Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2019-10-15 Earnings Release
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Earnings Release 2019
Earnings Release Classification · 100% confidence The document is titled "Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2019" and contains key financial highlights (Net sales of USD 765 million for Q3 2019). This structure—announcing period-specific financial results briefly—points towards an Earnings Release (ER). However, the document is very short (11,373 characters) and explicitly includes an "Attachment" link to a file named "191015_CA49_Dara Q3 Sales". According to Rule #2 (The 'MENU VS MEAL' Rule), if a document is short and announces that a report is attached or published, it should be classified as a Report Publication Announcement (RPA). Since this is an announcement about sales figures for a specific quarter, it is announcing the availability of the detailed sales data/report, making RPA the most appropriate classification over ER, which usually contains the full results summary within the filing itself. Q3 2019
2019-10-15 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2019
Earnings Release Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding the net sales of a specific product (DARZALEX) for the third quarter of 2019. It provides key financial highlights (sales figures) rather than a full quarterly report. According to the filing definitions, an initial announcement of quarterly financial results (key highlights only) is classified as an Earnings Release (ER). Q3 2019
2019-10-15 English
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Share Issue/Capital Change Classification · 95% confidence The document is a company announcement from Genmab A/S regarding the grant of restricted stock units and warrants to employees. While it mentions the grant of equity-based incentives, it does not report a specific transaction in the company's own shares (buyback) or a major shareholding notification. It is a regulatory announcement regarding corporate capital structure and incentive programs. Given the specific nature of the announcement regarding share-based compensation and the lack of a better fit for 'share issuance' (which usually implies public offerings or capital raises), it falls under the general regulatory filing category for corporate announcements.
2019-10-11 English
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Remuneration Information Classification · 99% confidence The document is a 'Company Announcement' dated October 11, 2019, detailing the decision by the board to grant restricted stock units and warrants to employees. This action directly relates to the company's capital structure, employee compensation, and share issuance mechanisms, but it is specifically about the issuance of equity instruments (stock units and warrants) to employees, which falls under changes in capital structure or insider transactions related to equity. Since the core event is the grant of stock units and warrants, this is best classified as a Capital/Financing Update (CAP) or potentially a Share Issue/Capital Change (SHA). Given the context of granting equity awards (which is a form of capital management/financing activity), CAP is a strong fit. However, the specific nature of granting stock units and warrants is often grouped with share issuance activities. Comparing the definitions, 'Capital/Financing Update (CAP)' covers fundraising and capital structure changes, while 'Share Issue/Capital Change (SHA)' covers new share issues or capital changes. The grant of stock units and warrants is a direct change to the potential share capital pool and is a common financing/compensation tool. Since the document is a formal announcement of the grant terms, it is a direct report on a capital structure event, making CAP or SHA appropriate. SHA is slightly more specific to the mechanics of issuing shares/rights. Let's re-evaluate: This is not a general fundraising announcement (CAP), but a specific grant of equity awards. This is a form of capital change/share issuance. Therefore, SHA is the most precise fit for reporting the grant of restricted stock units and warrants.
2019-10-11 English
6-K
Foreign Filer Report
2019-10-02 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement from Genmab A/S detailing an increase in share capital resulting from the exercise of employee warrants. It specifies the number of shares issued, the subscription prices, and the resulting total share capital. This falls directly under the definition of a 'Share Issue/Capital Change' (SHA) filing, as it describes a change in the company's capital structure due to the issuance of new shares.
2019-10-01 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.